Phase 3
Completed N=70
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
Source: ClinicalTrials.gov NCT00829296 ↗Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcomePrimary: Change in Central Systolic Blood Pressure (SBP) — 125.3; 127.8; 121.6; 123.8 mmHg
Summary
The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Central Systolic Blood Pressure (SBP) |
125.3; 127.8; 121.6; 123.8 | — |
| SECONDARY Change in Pulse Wave Velocity (PWV) |
6.48; 6.52; 6.3; 6.4 | — |
| SECONDARY Change in Augmentation Index |
22.0; 26.2; 22.1; 24.6 | — |
| SECONDARY Change in Pulse Pressure Amplification |
0.77; 0.79; 0.83; 0.85 | — |
Eligibility Criteria
Inclusion Criteria
- Established Type 2 diabetic not treated with insulin
- Stage 1 hypertensives blood pressure > 130/80 mmHg and 160mmHg or diastolic blood pressure > 100 mmHg
Data sourced from ClinicalTrials.gov (NCT00829296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.